Author: Ravi Shankar

Fairfax, Virginia, Sept. 22, 2026 (GLOBE NEWSWIRE) — Visium Technologies, Inc. (OTCID: VISM) (the “Company”) today announced that it has executed a non-binding term sheet with counterparties concerning a proposed assignment of specified contract-use, offtake, and deployment rights.

Under the term sheet, those rights would be assigned into a newly formed Indonesian limited-liability PMA company. A wholly owned Delaware subsidiary of the Company would hold a 99 percent interest in that PMA company. The proposed transaction is an assignment of identified rights. It is not an acquisition of the equity of any existing operating company. It would not cause the Company to manufacture semiconductor devices or to assume historical liabilities of the design firm.

Paul R. Taylor, Chairman and Chief Executive Officer, said: “Markets do not pay for adjectives. They pay for rights that survive a closing. We are not announcing a factory, a partner, or a watt. We are putting a defined bundle of rights into a clean vehicle, leaving every inherited liability where it belongs, and refusing to call the work finished until the last condition exists in fact.”

The term sheet is non-binding except for customary provisions on exclusivity, confidentiality, expenses, and governing law. Economic terms remain subject to Board authorization. Any closing consideration is expected to consist of a newly designated series of non-voting convertible preferred stock issued in a private placement under Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b). No cash is payable at a closing unless the Board separately authorizes a cash component.

Closing, if it occurs, remains subject to conditions that have not been satisfied, including written device specifications, required third-party and change-of-control consents, U.S. export-control classification and screening, Indonesian corporate and special-economic-zone approvals, site rights that survive closing, and corporate approvals required under Florida law. There can be no assurance that those conditions will be satisfied, that a definitive agreement will be executed, or that the transaction will close on the contemplated terms or at all.

Certain persons who beneficially own voting securities of the Company, and the Company’s Chairman and Chief Executive Officer, have relationships with parties expected to participate in the negotiation or performance of the proposed transaction. Those relationships will be disclosed in the Company’s filings to the extent required by the Exchange Act and Florida law. The term sheet requires review under Section 607.0832 of the Florida Business Corporation Act. That review has not been completed.

The Company is not announcing a partnership, a manufacturing arrangement, allocated power capacity, or projected revenue. The Company will file a Current Report on Form 8-K if and when it enters a material definitive agreement or completes a transaction that requires disclosure under the Exchange Act. Investors should rely solely on the Company’s filings with the Securities and Exchange Commission.

About Visium Technologies, Inc.
Visium Technologies, Inc. is a publicly traded technology holding company headquartered in Fairfax, Virginia. The company focuses on advanced technology platforms, AI-driven operational systems, analytics, and enterprise intelligence solutions.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to platform capabilities, anticipated operational benefits, customer adoption, future deployments, and market opportunities. Actual results may differ materially from those expressed or implied due to a variety of risks and uncertainties, including technology performance, market conditions, customer adoption rates, regulatory considerations, and other factors. Visium Technologies, Inc. undertakes no obligation to update forward-looking statements except as required by applicable law.

Media Contacts
Visium Technologies — Press: press@visiumtechnologies.com
Visium Technologies — Investor Relations: ir@visiumtechnologies.com
IR Concierge: 888-344-9850
Visium Technologies

Initial tranche assists CannEpil® development and commercialization

Financing comes as FDA and Congress increase focus on advancing and incentivizing regulated development of botanical and plant-derived medicines

FORT LAUDERDALE, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) — Endovia Health Sciences, Inc. (NYSE American: EDVA) (“Endovia” or the “Company”), a cannabinoid health sciences company, today announced that it has closed initial funding from C/M Capital Master Fund, LP (“C/M Capital”), representing the first tranche investment commitment previously announced in connection with the Company’s exclusive global licensing agreement for CannEpil® with Argent BioPharma Limited.

The capital is to advance the development and commercialization of CannEpil®, including Endovia’s U.S. FDA-regulated veterinary development program and international commercialization initiatives.

Endovia’s acquisition of exclusive worldwide rights to CannEpil®. C/M Capital committed capital to support regulatory advancement, clinical development planning and commercialization of the product.

“When we acquired the global rights to CannEpil, we laid out a clear strategy: secure a differentiated pharmaceutical cannabinoid asset, capitalize the program, advance it through established regulatory pathways and build a broader cannabinoid health sciences platform around it,” said Brady Cobb, Interim Chief Executive Officer of Endovia Health Sciences. “With this initial funding now closed, we are putting capital directly behind that strategy at what we believe is an increasingly important time for cannabinoid science and federal regulatory policy.”

Advancing CannEpil® Through Established FDA Pathways

The financing follows a series of milestones for Endovia’s CannEpil® development program.

The U.S. Food and Drug Administration’s Center for Veterinary Medicine previously established Investigational New Animal Drug (“INAD”) File No. 14145 for the CannEpil® veterinary development program, formally initiating the FDA regulatory process for development of CannEpil® as an investigational veterinary pharmaceutical.

Endovia is initially pursuing CannEpil® for the management of cancer-related pain in companion animals, beginning with canine oncology, and is working with Lupvindol Biosciences Ltd., its veterinary development partner, to advance the program through the applicable FDA regulatory process.

The Company also continues to pursue international commercialization opportunities for CannEpil® and evaluate additional cannabinoid formulations and intellectual property for potential licensing, acquisition or strategic collaboration.

Federal Momentum Toward Botanical Drug Development

Endovia believes its investment in cannabinoid pharmaceutical development is occurring against an increasingly constructive federal backdrop for the scientific development of botanical and plant-derived medicines.

The FDA recently launched an initiative seeking public input on opportunities to advance botanical drug development in the United States, including regulatory challenges facing botanical drug developers, innovative approaches to accelerate development, potential updates to FDA guidance and resources, quality standards and clinical study design. The initiative builds upon the FDA’s existing botanical drug regulatory framework, under which plant-derived products may be developed through established FDA drug-approval pathways. FDA materials addressing drug development from the cannabis plant have also identified the Agency’s botanical drug guidance as applicable to the use of botanicals, including cannabis, as sources for drug development.

Congress is also considering new incentives intended to encourage investment in FDA-regulated botanical medicines. On August 27, 2026, Representatives Lauren Boebert and Derrick Van Orden introduced H.R. 10150, the Advancing Botanical Drug Development Act of 2026, which was referred to the House Committee on Energy and Commerce. The proposed legislation would amend Section 505 of the Federal Food, Drug, and Cosmetic Act to provide qualifying botanical drugs approved through the FDA’s Section 505(b)(1) pathway with a 12-year period of market exclusivity, during which certain subsequent applications relying upon the approved botanical drug could not become effective.

In its findings, H.R. 10150 recognizes both the scientific potential and unique development challenges associated with botanical medicines and states that existing intellectual-property and regulatory-exclusivity frameworks may provide insufficient incentives for private investment in botanical drug research and development. The legislation expressly seeks to encourage the development and approval of evidence-based, FDA-regulated botanical drugs while maintaining the safety and effectiveness standards applicable to other FDA-regulated drugs.

“We believe these developments are significant for the broader cannabinoid sciences industry,” Cobb said. “The FDA already has an established regulatory framework for botanical drug development, and cannabis has been recognized within the Agency’s botanical drug development materials. We are now seeing renewed attention from both FDA and Congress around how sophisticated plant-derived medicines can be developed, evaluated and ultimately brought to market through rigorous, science-based regulatory pathways.”

Cobb continued, “The proposed 12-year exclusivity period is particularly noteworthy because access to capital and protection of the substantial investment required for pharmaceutical development are critical to building viable programs around complex plant-derived medicines. While H.R. 10150 remains proposed legislation, we believe its introduction, together with FDA’s renewed focus on botanical drug development, reflects meaningful federal attention to creating an environment capable of supporting greater scientific and private-sector investment in this area.”

About Endovia Health Sciences

Endovia Health Sciences, Inc. (NYSE American: EDVA) is a cannabinoid health sciences company focused on building a diversified platform across pharmaceutical development, FDA-regulated human and veterinary therapeutics, international pharmaceutical commercialization and cannabinoid-based wellness products.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of applicable federal securities laws, including statements regarding the development and commercialization of CannEpil®; the intended use and anticipated benefits of financing proceeds; future funding; FDA and other regulatory activities; potential changes in federal laws, regulations and policies affecting botanical drugs, cannabis and cannabinoids; plans and expectations for commercialization efforts including for veterinary uses and U.S. and international commercialization; potential licensing and acquisition opportunities; and the Company’s strategy to develop and expand its cannabinoid health sciences platform.

Forward-looking statements are based on current expectations, estimates, projections and assumptions and involve risks and uncertainties that could cause actual results to differ materially. These risks include the Company’s ability to obtain additional financing; successfully develop, obtain regulatory authorization for and commercialize CannEpil® or other products; maintain its rights under applicable license agreements; the enactment, implementation or impact of proposed legislation or regulatory initiatives; the occurrence of greater scientific and private-sector investment in botanical drug pathways, our ability to identify and consummate licensing, acquisition or strategic transactions; comply with NYSE American continued listing standards; and successfully execute our business strategy, our ability to complete required studies, establish product safety and efficacy, obtain and maintain regulatory authorizations, the risk that competitors market the same or similar products, our ability execute commercialization or strategic-partnering arrangements, the risk that that the market or demand for any resulting product we seek to commercialize in the future could be less than expected or projected, our ability to meet our debt obligations and the negative financial and operational consequences of failing to do so, the possibility that our expectations and perceived benefits with respect to our business and product development plan and strategic transactions we may pursue prove to be incorrect, and risks with respect to our ability to negotiate and execute definitive agreements, satisfy closing conditions, obtain required approvals with respect to any such strategic transaction. There can be no assurance that the Company’s goals and milestones will be achieved, that the Company or its collaborators will receive or maintain necessary regulatory authorizations or that any initiative will ultimately generate revenue.

There can be no assurance that additional funding will be received, H.R. 10150 or other proposed legislation will be enacted in its current form or at all, regulatory policies will change, regulatory or commercialization milestones will be achieved, or any product or initiative will ultimately generate revenue. Additional risks are described in the Company’s filings with the U.S. Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, the Form S-1 filed on August 7, 2026, as amended, and the final prospectus filed pursuant to Rule 424(b)(3) on August 28, 2026.

Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise any such statements whether as a result of new information, future events or otherwise, except as required by applicable law.

Investor Contact
Endovia Health Sciences
investors@endoviasciences.com

Media Contact
Angela Gorman
AMWPR
angela@amwpr.com
917-348-0083

Initial tranche assists CannEpil® development and commercialization

Financing comes as FDA and Congress increase focus on advancing and incentivizing regulated development of botanical and plant-derived medicines

FORT LAUDERDALE, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) — Endovia Health Sciences, Inc. (NYSE American: EDVA) (“Endovia” or the “Company”), a cannabinoid health sciences company, today announced that it has closed initial funding from C/M Capital Master Fund, LP (“C/M Capital”), representing the first tranche investment commitment previously announced in connection with the Company’s exclusive global licensing agreement for CannEpil® with Argent BioPharma Limited.

The capital is to advance the development and commercialization of CannEpil®, including Endovia’s U.S. FDA-regulated veterinary development program and international commercialization initiatives.

Endovia’s acquisition of exclusive worldwide rights to CannEpil®. C/M Capital committed capital to support regulatory advancement, clinical development planning and commercialization of the product.

“When we acquired the global rights to CannEpil, we laid out a clear strategy: secure a differentiated pharmaceutical cannabinoid asset, capitalize the program, advance it through established regulatory pathways and build a broader cannabinoid health sciences platform around it,” said Brady Cobb, Interim Chief Executive Officer of Endovia Health Sciences. “With this initial funding now closed, we are putting capital directly behind that strategy at what we believe is an increasingly important time for cannabinoid science and federal regulatory policy.”

Advancing CannEpil® Through Established FDA Pathways

The financing follows a series of milestones for Endovia’s CannEpil® development program.

The U.S. Food and Drug Administration’s Center for Veterinary Medicine previously established Investigational New Animal Drug (“INAD”) File No. 14145 for the CannEpil® veterinary development program, formally initiating the FDA regulatory process for development of CannEpil® as an investigational veterinary pharmaceutical.

Endovia is initially pursuing CannEpil® for the management of cancer-related pain in companion animals, beginning with canine oncology, and is working with Lupvindol Biosciences Ltd., its veterinary development partner, to advance the program through the applicable FDA regulatory process.

The Company also continues to pursue international commercialization opportunities for CannEpil® and evaluate additional cannabinoid formulations and intellectual property for potential licensing, acquisition or strategic collaboration.

Federal Momentum Toward Botanical Drug Development

Endovia believes its investment in cannabinoid pharmaceutical development is occurring against an increasingly constructive federal backdrop for the scientific development of botanical and plant-derived medicines.

The FDA recently launched an initiative seeking public input on opportunities to advance botanical drug development in the United States, including regulatory challenges facing botanical drug developers, innovative approaches to accelerate development, potential updates to FDA guidance and resources, quality standards and clinical study design. The initiative builds upon the FDA’s existing botanical drug regulatory framework, under which plant-derived products may be developed through established FDA drug-approval pathways. FDA materials addressing drug development from the cannabis plant have also identified the Agency’s botanical drug guidance as applicable to the use of botanicals, including cannabis, as sources for drug development.

Congress is also considering new incentives intended to encourage investment in FDA-regulated botanical medicines. On August 27, 2026, Representatives Lauren Boebert and Derrick Van Orden introduced H.R. 10150, the Advancing Botanical Drug Development Act of 2026, which was referred to the House Committee on Energy and Commerce. The proposed legislation would amend Section 505 of the Federal Food, Drug, and Cosmetic Act to provide qualifying botanical drugs approved through the FDA’s Section 505(b)(1) pathway with a 12-year period of market exclusivity, during which certain subsequent applications relying upon the approved botanical drug could not become effective.

In its findings, H.R. 10150 recognizes both the scientific potential and unique development challenges associated with botanical medicines and states that existing intellectual-property and regulatory-exclusivity frameworks may provide insufficient incentives for private investment in botanical drug research and development. The legislation expressly seeks to encourage the development and approval of evidence-based, FDA-regulated botanical drugs while maintaining the safety and effectiveness standards applicable to other FDA-regulated drugs.

“We believe these developments are significant for the broader cannabinoid sciences industry,” Cobb said. “The FDA already has an established regulatory framework for botanical drug development, and cannabis has been recognized within the Agency’s botanical drug development materials. We are now seeing renewed attention from both FDA and Congress around how sophisticated plant-derived medicines can be developed, evaluated and ultimately brought to market through rigorous, science-based regulatory pathways.”

Cobb continued, “The proposed 12-year exclusivity period is particularly noteworthy because access to capital and protection of the substantial investment required for pharmaceutical development are critical to building viable programs around complex plant-derived medicines. While H.R. 10150 remains proposed legislation, we believe its introduction, together with FDA’s renewed focus on botanical drug development, reflects meaningful federal attention to creating an environment capable of supporting greater scientific and private-sector investment in this area.”

About Endovia Health Sciences

Endovia Health Sciences, Inc. (NYSE American: EDVA) is a cannabinoid health sciences company focused on building a diversified platform across pharmaceutical development, FDA-regulated human and veterinary therapeutics, international pharmaceutical commercialization and cannabinoid-based wellness products.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of applicable federal securities laws, including statements regarding the development and commercialization of CannEpil®; the intended use and anticipated benefits of financing proceeds; future funding; FDA and other regulatory activities; potential changes in federal laws, regulations and policies affecting botanical drugs, cannabis and cannabinoids; plans and expectations for commercialization efforts including for veterinary uses and U.S. and international commercialization; potential licensing and acquisition opportunities; and the Company’s strategy to develop and expand its cannabinoid health sciences platform.

Forward-looking statements are based on current expectations, estimates, projections and assumptions and involve risks and uncertainties that could cause actual results to differ materially. These risks include the Company’s ability to obtain additional financing; successfully develop, obtain regulatory authorization for and commercialize CannEpil® or other products; maintain its rights under applicable license agreements; the enactment, implementation or impact of proposed legislation or regulatory initiatives; the occurrence of greater scientific and private-sector investment in botanical drug pathways, our ability to identify and consummate licensing, acquisition or strategic transactions; comply with NYSE American continued listing standards; and successfully execute our business strategy, our ability to complete required studies, establish product safety and efficacy, obtain and maintain regulatory authorizations, the risk that competitors market the same or similar products, our ability execute commercialization or strategic-partnering arrangements, the risk that that the market or demand for any resulting product we seek to commercialize in the future could be less than expected or projected, our ability to meet our debt obligations and the negative financial and operational consequences of failing to do so, the possibility that our expectations and perceived benefits with respect to our business and product development plan and strategic transactions we may pursue prove to be incorrect, and risks with respect to our ability to negotiate and execute definitive agreements, satisfy closing conditions, obtain required approvals with respect to any such strategic transaction. There can be no assurance that the Company’s goals and milestones will be achieved, that the Company or its collaborators will receive or maintain necessary regulatory authorizations or that any initiative will ultimately generate revenue.

There can be no assurance that additional funding will be received, H.R. 10150 or other proposed legislation will be enacted in its current form or at all, regulatory policies will change, regulatory or commercialization milestones will be achieved, or any product or initiative will ultimately generate revenue. Additional risks are described in the Company’s filings with the U.S. Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, the Form S-1 filed on August 7, 2026, as amended, and the final prospectus filed pursuant to Rule 424(b)(3) on August 28, 2026.

Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise any such statements whether as a result of new information, future events or otherwise, except as required by applicable law.

Investor Contact
Endovia Health Sciences
investors@endoviasciences.com

Media Contact
Angela Gorman
AMWPR
angela@amwpr.com
917-348-0083

Expansion demonstrates the portability of Cloudastructure’s AI-powered security platform across large enterprise real estate portfolios

PALO ALTO, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) — Cloudastructure, Inc. (“Cloudastructure” or the “Company”) (NASDAQ: CSAI), a leader in cloud-native AI surveillance and remote guarding, today announced its expansion into the industrial and supply chain security market, marking the Company’s entry into a new enterprise vertical beyond its established multifamily business. The expansion is anchored by a deepening relationship with one of the world’s largest commercial real estate services and investment firms and further demonstrates Cloudastructure’s strategy of growing alongside large enterprise customers as their security needs evolve.

The customer’s portfolio spans office, industrial, retail and logistics properties nationwide. Cloudastructure’s footprint across the portfolio has more than doubled this year, expanding beyond its original multifamily deployments into industrial and logistics assets, including its first industrial warehouse supporting mission-critical supply chain operations. The customer had previously utilized another remote guarding provider at the site before selecting Cloudastructure’s AI Surveillance and Remote Guarding platform based on its ability to proactively deter incidents while reducing total cost of ownership.

Industrial warehouses present an ideal application for AI-powered remote guarding, combining expansive perimeters, high-value inventory and limited onsite personnel. These characteristics make proactive detection and intervention significantly more valuable than traditional surveillance systems designed primarily to record incidents after they occur. Industry losses from cargo and warehouse incidents were estimated at $725 million in 2025, a 60% increase over the prior year,¹ with 41% of incidents occurring while goods were in storage rather than in transit.² These trends continue to drive demand for intelligent security platforms capable of preventing incidents in real time rather than simply documenting them.

“Customers are no longer buying cameras. They’re buying deterrence. They want to prevent incidents before they happen, reduce operating costs and improve security across their portfolios,” said James McCormick, Chief Executive Officer of Cloudastructure. “We built our platform as a cloud-native solution from day one so we can deliver those outcomes across multifamily, industrial and other enterprise environments without changing the underlying technology.”

Mr. McCormick continued, “This deployment represents much more than another site. It reflects our ability to grow alongside our enterprise customers as their security needs evolve. Expanding into industrial and logistics within one of the world’s largest commercial real estate portfolios validates our land-and-expand strategy and reinforces our belief that the same cloud-native platform can solve security challenges across virtually any enterprise real estate environment.”

Industrial and supply chain security is the Company’s newest enterprise vertical alongside multifamily and commercial real estate. Cloudastructure now supports nine sites across this customer’s portfolio, up from five at the start of the year. Across its deployments, the Company maintains a 98% deterrence rate against criminal activity and customer retention of approximately 99%. Management believes these results demonstrate the scalability of the Company’s platform and support additional expansion opportunities across large enterprise real estate portfolios.

^{[1] Verisk CargoNet, 2025 Cargo Theft Report: cargonet.com/news-and-events/cargonet-in-the-media/2025-theft-trends
[2] Trade Risk Guaranty, U.S. Domestic Cargo Theft – 2024 Trends: traderiskguaranty.com/trgpeak/u-s-domestic-cargo-theft-rise-2024}

About Cloudastructure
Headquartered in Palo Alto, California, Cloudastructure’s patented, advanced, award-winning security platform utilizes a scalable cloud-based architecture that features cloud video surveillance with proprietary, state-of-the-art AI/ML analytics, and a seamless remote guarding solution. The combination enables enterprise businesses to achieve proactive, end-to-end security, and pairs that platform with an attractive value proposition that eschews proprietary hardware and offers contract-free, month-to-month pricing and unlimited 24/7 support. With Cloudastructure, companies can achieve unparalleled situational awareness in real time and thereby stop crime as it is happening, while simultaneously achieving up to a 75% lower Total Cost of Ownership than other systems. For more information, visit https://www.cloudastructure.com/.

Forward-Looking Statements

Certain statements in this press release may be considered forward-looking, such as statements containing estimates, projections, and other forward-looking information. Forward-looking statements are typically identified by words and phrases such as “anticipate,” “estimate,” “believe,” “continue,” “could,” “intend,” “may,” “plan,” “potential,” “predict,” “seek,” “should,” “will,” “would,” “expect,” “objective,” “projection,” “forecast,” “goal,” “guidance,” “outlook,” “effort,” “target” or the negative of such words and other comparable terminology. However, the absence of these words does not mean that a statement is not forward-looking. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and involve risks, uncertainties, and other factors beyond our control. Therefore, we caution you against relying on any of these forward-looking statements. Factors that could cause or contribute to such differences include the risks and uncertainties discussed in the reports that the Company has filed with the SEC, such as its Annual Report on Form 10-K. Actual outcomes and results may differ materially from what is expressed in any forward-looking statement. Except as required by applicable law, including U.S. federal securities laws, we do not intend to update any of the forward-looking statements to conform them to actual results or revised expectations.

Media Contact

Kathleen Hannon, Sr. Communications Director
Cloudastructure, Inc.
704.574.3732
Kathleen@cloudastructure.com

Investor Contact

Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Cloudastructure@KCSA.com

Expansion demonstrates the portability of Cloudastructure’s AI-powered security platform across large enterprise real estate portfolios

PALO ALTO, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) — Cloudastructure, Inc. (“Cloudastructure” or the “Company”) (NASDAQ: CSAI), a leader in cloud-native AI surveillance and remote guarding, today announced its expansion into the industrial and supply chain security market, marking the Company’s entry into a new enterprise vertical beyond its established multifamily business. The expansion is anchored by a deepening relationship with one of the world’s largest commercial real estate services and investment firms and further demonstrates Cloudastructure’s strategy of growing alongside large enterprise customers as their security needs evolve.

The customer’s portfolio spans office, industrial, retail and logistics properties nationwide. Cloudastructure’s footprint across the portfolio has more than doubled this year, expanding beyond its original multifamily deployments into industrial and logistics assets, including its first industrial warehouse supporting mission-critical supply chain operations. The customer had previously utilized another remote guarding provider at the site before selecting Cloudastructure’s AI Surveillance and Remote Guarding platform based on its ability to proactively deter incidents while reducing total cost of ownership.

Industrial warehouses present an ideal application for AI-powered remote guarding, combining expansive perimeters, high-value inventory and limited onsite personnel. These characteristics make proactive detection and intervention significantly more valuable than traditional surveillance systems designed primarily to record incidents after they occur. Industry losses from cargo and warehouse incidents were estimated at $725 million in 2025, a 60% increase over the prior year,¹ with 41% of incidents occurring while goods were in storage rather than in transit.² These trends continue to drive demand for intelligent security platforms capable of preventing incidents in real time rather than simply documenting them.

“Customers are no longer buying cameras. They’re buying deterrence. They want to prevent incidents before they happen, reduce operating costs and improve security across their portfolios,” said James McCormick, Chief Executive Officer of Cloudastructure. “We built our platform as a cloud-native solution from day one so we can deliver those outcomes across multifamily, industrial and other enterprise environments without changing the underlying technology.”

Mr. McCormick continued, “This deployment represents much more than another site. It reflects our ability to grow alongside our enterprise customers as their security needs evolve. Expanding into industrial and logistics within one of the world’s largest commercial real estate portfolios validates our land-and-expand strategy and reinforces our belief that the same cloud-native platform can solve security challenges across virtually any enterprise real estate environment.”

Industrial and supply chain security is the Company’s newest enterprise vertical alongside multifamily and commercial real estate. Cloudastructure now supports nine sites across this customer’s portfolio, up from five at the start of the year. Across its deployments, the Company maintains a 98% deterrence rate against criminal activity and customer retention of approximately 99%. Management believes these results demonstrate the scalability of the Company’s platform and support additional expansion opportunities across large enterprise real estate portfolios.

^{[1] Verisk CargoNet, 2025 Cargo Theft Report: cargonet.com/news-and-events/cargonet-in-the-media/2025-theft-trends
[2] Trade Risk Guaranty, U.S. Domestic Cargo Theft – 2024 Trends: traderiskguaranty.com/trgpeak/u-s-domestic-cargo-theft-rise-2024}

About Cloudastructure
Headquartered in Palo Alto, California, Cloudastructure’s patented, advanced, award-winning security platform utilizes a scalable cloud-based architecture that features cloud video surveillance with proprietary, state-of-the-art AI/ML analytics, and a seamless remote guarding solution. The combination enables enterprise businesses to achieve proactive, end-to-end security, and pairs that platform with an attractive value proposition that eschews proprietary hardware and offers contract-free, month-to-month pricing and unlimited 24/7 support. With Cloudastructure, companies can achieve unparalleled situational awareness in real time and thereby stop crime as it is happening, while simultaneously achieving up to a 75% lower Total Cost of Ownership than other systems. For more information, visit https://www.cloudastructure.com/.

Forward-Looking Statements

Certain statements in this press release may be considered forward-looking, such as statements containing estimates, projections, and other forward-looking information. Forward-looking statements are typically identified by words and phrases such as “anticipate,” “estimate,” “believe,” “continue,” “could,” “intend,” “may,” “plan,” “potential,” “predict,” “seek,” “should,” “will,” “would,” “expect,” “objective,” “projection,” “forecast,” “goal,” “guidance,” “outlook,” “effort,” “target” or the negative of such words and other comparable terminology. However, the absence of these words does not mean that a statement is not forward-looking. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and involve risks, uncertainties, and other factors beyond our control. Therefore, we caution you against relying on any of these forward-looking statements. Factors that could cause or contribute to such differences include the risks and uncertainties discussed in the reports that the Company has filed with the SEC, such as its Annual Report on Form 10-K. Actual outcomes and results may differ materially from what is expressed in any forward-looking statement. Except as required by applicable law, including U.S. federal securities laws, we do not intend to update any of the forward-looking statements to conform them to actual results or revised expectations.

Media Contact

Kathleen Hannon, Sr. Communications Director
Cloudastructure, Inc.
704.574.3732
Kathleen@cloudastructure.com

Investor Contact

Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Cloudastructure@KCSA.com

Industry accolade highlights Cyabra’s technical innovation, commercial momentum, and market leadership in protecting organizations against AI-driven manipulation and narrative threats

New York, NY, Sept. 22, 2026 (GLOBE NEWSWIRE) — Cyabra, Inc. (Nasdaq: CYAB) (“Cyabra” or the “Company”), an artificial intelligence (“AI”)-powered platform that helps governments and enterprises detect coordinated manipulation and protect digital trust, today announced it has been recognized as the AI-powered Enterprise Solution of the Year by the 2026 Tech Ascension Awards.

“The pace of artificial intelligence (AI) innovation is extraordinary, but Cyabra distinguished itself by turning technical innovation into practical value,” said David Campbell, Chief Executive Officer of the Tech Ascension Awards. “Cyabra addresses meaningful industry challenges with a differentiated approach and demonstrated business impact. It represents the kind of purposeful innovation that is shaping the future of AI.”

The 2026 Tech Ascension Awards attracted an unprecedented number of submissions from companies competing across enterprise AI, agentic automation and small-business technology categories. This record participation reflects the rapid growth of the AI industry and the accelerating pace at which organizations are bringing advanced capabilities to market.

“We view being named AI-powered Enterprise Solution of the Year by the Tech Ascension Awards as validation of our team’s commitment to turning complex AI technology into a vital defense capability for global organizations,” said Dan Brahmy, Co-Founder and Chief Executive Officer of Cyabra. “As generative AI makes digital manipulation faster, cheaper, and harder to spot, enterprise and public sector leaders need decision-grade intelligence to safeguard trust. We believe this recognition reflects our ongoing momentum as we scale our platform to protect the world’s leading brands and sovereign entities.”

This achievement builds on Cyabra’s recent recognition as a Market Shaper in the inaugural June 2026 Gartner® Emerging Market Quadrant for Narrative Intelligence – Startup Vendors, in which Gartner, Inc. formally defined and assessed the narrative intelligence market for the first time¹.

About Cyabra

Cyabra is an AI-powered narrative intelligence company that helps national security and defense organizations, government agencies, brands, communications agencies, and global enterprises restore trust and authenticity online by analyzing manipulated content, coordinated behaviors, and inauthentic actors. The platform helps teams understand who is operating, how activity is amplified, and where coordinated activity is shaping perception, translating evidence into clear mitigation steps. By reducing ambiguity and misdirected response, Cyabra enables proportionate, evidence-led action when clarity matters most.

For more information, visit www.cyabra.com.

Contact

Investors: ir@cyabra.com
Media: pr@cyabra.com

About the Tech Ascension Awards

The Tech Ascension Awards recognize companies whose innovative technologies solve critical challenges in their respective markets. Tech Ascension Award recipients rise above crowded consumer and enterprise technology sectors and receive validation from an independent awards program. Applicants are evaluated based on technological innovation and uniqueness, market research, analyst reports, media coverage, customer case studies, demonstrated performance results and competitive differentiation. The awards recognize leaders across cybersecurity, artificial intelligence, DevOps, big data and other technology categories. For more information about the Tech Ascension Awards, please visit www.techascensionawards.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical statements of fact and statements regarding Cyabra’s intent, belief, or expectations, including, but not limited to, statements regarding Cyabra’s future results of operations and financial position, planned products and services, business strategy and plans, market size and growth opportunities, competitive position and market trends. Some of these forward-looking statements can be identified by the use of forward-looking words, including “may,” “should,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” “plan,” “targets,” “projects,” “could,” “would,” “continue,” “forecast” or the negatives of these terms or variations of them or similar expressions. For example, the Company is using forward-looking statements in this press release when it discusses its belief that the award is validation of its team’s commitment to turning complex AI technology into a vital defense capability for global organizations, that Cyabra represents purposeful innovation that is shaping the future of artificial intelligence and its belief that this recognition reflects its ongoing momentum as it scales its platform to protect the world’s leading brands and sovereign entities. These statements relate to future events and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in Cyabra’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. Cyabra undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

_______________________

1 GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.

Industry accolade highlights Cyabra’s technical innovation, commercial momentum, and market leadership in protecting organizations against AI-driven manipulation and narrative threats

New York, NY, Sept. 22, 2026 (GLOBE NEWSWIRE) — Cyabra, Inc. (Nasdaq: CYAB) (“Cyabra” or the “Company”), an artificial intelligence (“AI”)-powered platform that helps governments and enterprises detect coordinated manipulation and protect digital trust, today announced it has been recognized as the AI-powered Enterprise Solution of the Year by the 2026 Tech Ascension Awards.

“The pace of artificial intelligence (AI) innovation is extraordinary, but Cyabra distinguished itself by turning technical innovation into practical value,” said David Campbell, Chief Executive Officer of the Tech Ascension Awards. “Cyabra addresses meaningful industry challenges with a differentiated approach and demonstrated business impact. It represents the kind of purposeful innovation that is shaping the future of AI.”

The 2026 Tech Ascension Awards attracted an unprecedented number of submissions from companies competing across enterprise AI, agentic automation and small-business technology categories. This record participation reflects the rapid growth of the AI industry and the accelerating pace at which organizations are bringing advanced capabilities to market.

“We view being named AI-powered Enterprise Solution of the Year by the Tech Ascension Awards as validation of our team’s commitment to turning complex AI technology into a vital defense capability for global organizations,” said Dan Brahmy, Co-Founder and Chief Executive Officer of Cyabra. “As generative AI makes digital manipulation faster, cheaper, and harder to spot, enterprise and public sector leaders need decision-grade intelligence to safeguard trust. We believe this recognition reflects our ongoing momentum as we scale our platform to protect the world’s leading brands and sovereign entities.”

This achievement builds on Cyabra’s recent recognition as a Market Shaper in the inaugural June 2026 Gartner® Emerging Market Quadrant for Narrative Intelligence – Startup Vendors, in which Gartner, Inc. formally defined and assessed the narrative intelligence market for the first time¹.

About Cyabra

Cyabra is an AI-powered narrative intelligence company that helps national security and defense organizations, government agencies, brands, communications agencies, and global enterprises restore trust and authenticity online by analyzing manipulated content, coordinated behaviors, and inauthentic actors. The platform helps teams understand who is operating, how activity is amplified, and where coordinated activity is shaping perception, translating evidence into clear mitigation steps. By reducing ambiguity and misdirected response, Cyabra enables proportionate, evidence-led action when clarity matters most.

For more information, visit www.cyabra.com.

Contact

Investors: ir@cyabra.com
Media: pr@cyabra.com

About the Tech Ascension Awards

The Tech Ascension Awards recognize companies whose innovative technologies solve critical challenges in their respective markets. Tech Ascension Award recipients rise above crowded consumer and enterprise technology sectors and receive validation from an independent awards program. Applicants are evaluated based on technological innovation and uniqueness, market research, analyst reports, media coverage, customer case studies, demonstrated performance results and competitive differentiation. The awards recognize leaders across cybersecurity, artificial intelligence, DevOps, big data and other technology categories. For more information about the Tech Ascension Awards, please visit www.techascensionawards.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical statements of fact and statements regarding Cyabra’s intent, belief, or expectations, including, but not limited to, statements regarding Cyabra’s future results of operations and financial position, planned products and services, business strategy and plans, market size and growth opportunities, competitive position and market trends. Some of these forward-looking statements can be identified by the use of forward-looking words, including “may,” “should,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” “plan,” “targets,” “projects,” “could,” “would,” “continue,” “forecast” or the negatives of these terms or variations of them or similar expressions. For example, the Company is using forward-looking statements in this press release when it discusses its belief that the award is validation of its team’s commitment to turning complex AI technology into a vital defense capability for global organizations, that Cyabra represents purposeful innovation that is shaping the future of artificial intelligence and its belief that this recognition reflects its ongoing momentum as it scales its platform to protect the world’s leading brands and sovereign entities. These statements relate to future events and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in Cyabra’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. Cyabra undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

_______________________

1 GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.

INFORMATION STATEMENT WILL BE ACCESSIBLE THROUGH SEDAR+

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

OTTAWA, Ontario, Sept. 22, 2026 (GLOBE NEWSWIRE) — (TSX: MNT/MNT.U) The Royal Canadian Mint (the ”Mint”) announced today that it has priced its previously-announced underwritten follow-on offering of exchange-traded receipts (“ETRs”) under the Mint’s Canadian Gold Reserves program at a price of C$65.82 per ETR (the ”Offering”). The underwriters for the Offering have agreed to purchase 501,175 ETRs for gross proceeds of C$32,987,338.50. The Mint’s outstanding ETRs are listed on the Toronto Stock Exchange in Canadian and U.S. dollars under the symbols “MNT” and “MNT.U”, respectively.

Each ETR provides its holder with direct legal and beneficial ownership in physical gold bullion held in the custody of the Mint at its facilities in Ottawa, Ontario. The ETRs to be issued under the Offering will be identical to and fully fungible with the ETRs currently outstanding. The net proceeds of the Offering will be used to purchase gold bullion on behalf of the purchasers of the ETRs.

Subject to certain restrictions, ETR holders are entitled to redeem their ETRs for physical gold bullion with a minimum purity of 99.99% or for cash.

The closing of the Offering is expected to take place on or about September 24, 2026 and will be subject to customary conditions, including approval of the Toronto Stock Exchange.

The Offering is being made by a syndicate of underwriters co-led by TD Securities Inc. and National Bank Financial Inc. and includes CIBC World Markets Inc., RBC Dominion Securities Inc., BMO Nesbitt Burns Inc., Scotia Capital Inc., Canaccord Genuity Corp., iA Private Wealth Inc., Raymond James Ltd., ATB Capital Markets Corp., Desjardins Securities Inc., Manulife Wealth Inc. and Hampton Securities Limited. The Offering is being made on a prospectus-exempt basis pursuant to the terms of exemptive relief orders issued in favour of the Mint by the Ontario Securities Commission.

Important information about the ETRs and the Offering is contained in the information statement dated September 22, 2026 (the “Information Statement”). The Information Statement will be accessible on SEDAR+ at www.sedarplus.ca and on the Mint’s website at www.reserves.mint.ca. Purchasers will be notified of the availability of the Information Statement through their investment dealer. In addition, a copy of the Information Statement may be obtained, without charge, from TD Securities Inc. (sdcconfirms@td.com by email or (289) 360-2009 by telephone) or National Bank Financial Inc. (NBF-Syndication@bnc.ca by email or (416) 869-8414 by telephone).

ETR holders have no recourse to the Mint or the Government of Canada for any loss on their investment.

The ETRs have not been and will not be registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any offer, solicitation or sale of the ETRs in any jurisdiction in which such an offer, solicitation or sale would be unlawful.

Additional information on the Canadian Gold Reserves program and the ETRs is available on the Canadian Gold Reserves’ website at www.reserves.mint.ca and on the Mint’s issuer profile on SEDAR+ at www.sedarplus.ca.

About the Royal Canadian Mint

The Royal Canadian Mint is the Crown corporation responsible for the minting and distribution of Canada’s circulation coins. The Mint is one of the largest and most versatile mints in the world, producing award-winning collector coins, market-leading bullion products, as well as Canada’s prestigious military and civilian honours. As an established London Good Delivery and COMEX-approved refiner, the Mint also offers a full spectrum of best-in-class gold and silver refining services. The Mint has issued exchange-traded receipts under its Canadian Gold Reserves (TSX: MNT/MNT.U) and Canadian Silver Reserves (TSX: MNS/MNS.U) programs, which provide holders with direct legal and beneficial ownership in physical bullion held in the custody of the Mint at its facilities. For more information on the Mint, its products and services, visit www.mint.ca.

Certain information in this news release contains forward-looking information within the meaning of applicable securities laws in Canada. The forward-looking information in this news release includes, without limitation, statements regarding the terms of the Offering. All forward-looking information is given pursuant to the safe harbour provisions of applicable Canadian securities legislation. The words “anticipates”, “believes”, “budgets”, “could”, “estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”, “projects”, “schedule”, “should”, “will”, “would” and similar expressions identify forward-looking information, although not all forward-looking information contains these identifying words. The forward-looking information reflects management’s current beliefs with respect to anticipated events, are based on assumptions developed using information currently available to the Mint’s management and are subject to inherent risks and uncertainties surrounding future expectations generally. Although the Mint believes that the forward-looking information is based on information and assumptions which are current, reasonable and complete, these statements are necessarily subject to a variety of risks and uncertainties. Forward-looking information should not be read as guarantees of future events, performance or results, and will not necessarily be accurate indications of whether, or the times at which, such events, performance or results will be achieved. All the information in this news release containing forward-looking information is qualified by these cautionary statements.

For additional information on risk factors that have the potential to affect the ETRs, the Canadian Gold Reserves program or the Mint, reference should be made to the Information Statement, which may be accessed in the manner described above. Readers are urged to consider the risks, uncertainties, and assumptions carefully in evaluating the forward-looking information and are cautioned not to place undue reliance on such information and statements.

Except as required by law, the Mint undertakes no obligation to revise or update any forward-looking information as a result of new information, future events or otherwise after the date hereof.

For more information, please contact:

Media Inquiries	Investor Relations
Alex Reeves	Frank Caterina
Senior Manager, Public Affairs	Program Associate, ETR Investor
Royal Canadian Mint	Relations
613-884-6370	Royal Canadian Mint
reeves@mint.ca	1-866-677-1477
	reserves@mint.ca

INFORMATION STATEMENT WILL BE ACCESSIBLE THROUGH SEDAR+

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

OTTAWA, Ontario, Sept. 22, 2026 (GLOBE NEWSWIRE) — (TSX: MNT/MNT.U) The Royal Canadian Mint (the ”Mint”) announced today that it has priced its previously-announced underwritten follow-on offering of exchange-traded receipts (“ETRs”) under the Mint’s Canadian Gold Reserves program at a price of C$65.82 per ETR (the ”Offering”). The underwriters for the Offering have agreed to purchase 501,175 ETRs for gross proceeds of C$32,987,338.50. The Mint’s outstanding ETRs are listed on the Toronto Stock Exchange in Canadian and U.S. dollars under the symbols “MNT” and “MNT.U”, respectively.

Each ETR provides its holder with direct legal and beneficial ownership in physical gold bullion held in the custody of the Mint at its facilities in Ottawa, Ontario. The ETRs to be issued under the Offering will be identical to and fully fungible with the ETRs currently outstanding. The net proceeds of the Offering will be used to purchase gold bullion on behalf of the purchasers of the ETRs.

Subject to certain restrictions, ETR holders are entitled to redeem their ETRs for physical gold bullion with a minimum purity of 99.99% or for cash.

The closing of the Offering is expected to take place on or about September 24, 2026 and will be subject to customary conditions, including approval of the Toronto Stock Exchange.

The Offering is being made by a syndicate of underwriters co-led by TD Securities Inc. and National Bank Financial Inc. and includes CIBC World Markets Inc., RBC Dominion Securities Inc., BMO Nesbitt Burns Inc., Scotia Capital Inc., Canaccord Genuity Corp., iA Private Wealth Inc., Raymond James Ltd., ATB Capital Markets Corp., Desjardins Securities Inc., Manulife Wealth Inc. and Hampton Securities Limited. The Offering is being made on a prospectus-exempt basis pursuant to the terms of exemptive relief orders issued in favour of the Mint by the Ontario Securities Commission.

Important information about the ETRs and the Offering is contained in the information statement dated September 22, 2026 (the “Information Statement”). The Information Statement will be accessible on SEDAR+ at www.sedarplus.ca and on the Mint’s website at www.reserves.mint.ca. Purchasers will be notified of the availability of the Information Statement through their investment dealer. In addition, a copy of the Information Statement may be obtained, without charge, from TD Securities Inc. (sdcconfirms@td.com by email or (289) 360-2009 by telephone) or National Bank Financial Inc. (NBF-Syndication@bnc.ca by email or (416) 869-8414 by telephone).

ETR holders have no recourse to the Mint or the Government of Canada for any loss on their investment.

The ETRs have not been and will not be registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any offer, solicitation or sale of the ETRs in any jurisdiction in which such an offer, solicitation or sale would be unlawful.

Additional information on the Canadian Gold Reserves program and the ETRs is available on the Canadian Gold Reserves’ website at www.reserves.mint.ca and on the Mint’s issuer profile on SEDAR+ at www.sedarplus.ca.

About the Royal Canadian Mint

The Royal Canadian Mint is the Crown corporation responsible for the minting and distribution of Canada’s circulation coins. The Mint is one of the largest and most versatile mints in the world, producing award-winning collector coins, market-leading bullion products, as well as Canada’s prestigious military and civilian honours. As an established London Good Delivery and COMEX-approved refiner, the Mint also offers a full spectrum of best-in-class gold and silver refining services. The Mint has issued exchange-traded receipts under its Canadian Gold Reserves (TSX: MNT/MNT.U) and Canadian Silver Reserves (TSX: MNS/MNS.U) programs, which provide holders with direct legal and beneficial ownership in physical bullion held in the custody of the Mint at its facilities. For more information on the Mint, its products and services, visit www.mint.ca.

Certain information in this news release contains forward-looking information within the meaning of applicable securities laws in Canada. The forward-looking information in this news release includes, without limitation, statements regarding the terms of the Offering. All forward-looking information is given pursuant to the safe harbour provisions of applicable Canadian securities legislation. The words “anticipates”, “believes”, “budgets”, “could”, “estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”, “projects”, “schedule”, “should”, “will”, “would” and similar expressions identify forward-looking information, although not all forward-looking information contains these identifying words. The forward-looking information reflects management’s current beliefs with respect to anticipated events, are based on assumptions developed using information currently available to the Mint’s management and are subject to inherent risks and uncertainties surrounding future expectations generally. Although the Mint believes that the forward-looking information is based on information and assumptions which are current, reasonable and complete, these statements are necessarily subject to a variety of risks and uncertainties. Forward-looking information should not be read as guarantees of future events, performance or results, and will not necessarily be accurate indications of whether, or the times at which, such events, performance or results will be achieved. All the information in this news release containing forward-looking information is qualified by these cautionary statements.

For additional information on risk factors that have the potential to affect the ETRs, the Canadian Gold Reserves program or the Mint, reference should be made to the Information Statement, which may be accessed in the manner described above. Readers are urged to consider the risks, uncertainties, and assumptions carefully in evaluating the forward-looking information and are cautioned not to place undue reliance on such information and statements.

Except as required by law, the Mint undertakes no obligation to revise or update any forward-looking information as a result of new information, future events or otherwise after the date hereof.

For more information, please contact:

Media Inquiries	Investor Relations
Alex Reeves	Frank Caterina
Senior Manager, Public Affairs	Program Associate, ETR Investor
Royal Canadian Mint	Relations
613-884-6370	Royal Canadian Mint
reeves@mint.ca	1-866-677-1477
	reserves@mint.ca

London, Sept. 22, 2026 (GLOBE NEWSWIRE) — RedCloud Holdings plc (the “Company” or “RedCloud”) (Nasdaq: RCT) today announced that it has entered into a subscription agreement and set-off agreement with Justin Floyd, the Company’s Chief Executive Officer, pursuant to which the Company agreed to issue and sell 74,000 of its unregistered ordinary shares to Mr. Floyd in a private placement at a price per share of $2.50, representing a substantial premium to the closing price of the Company’s ordinary shares on September 21, 2026, for an aggregate subscription price of $185,000. The aggregate subscription price will be paid to the Company by offsetting financial liabilities of the Company owed to Mr. Floyd. The Company expects to complete the issuance on or about September 22, 2026.

The ordinary shares to be issued in connection with the private placement described above are being offered in a private placement and have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state or other applicable jurisdictions’ securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions’ securities laws.

This news release does not constitute an offer to sell or the solicitation of an offer to buy the ordinary shares described herein, nor shall there be any sale of these ordinary shares in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About RedCloud Holdings plc

RedCloud’s mission is to build the intelligence infrastructure of global trade, through generation and aggregation of proprietary trading and market data from across the FMCG industry through its RedAI infrastructure and associated products (“RedAI”). RedCloud provides market intelligence based on proprietary trading data across categories in each of its markets. The Company also delivers a trading infrastructure and related products for use by its customers, to enable intelligent digital exchange of everyday consumer supplies of FMCG products across business supply chains.

RedCloud is a British company registered in London, co-founded by serial entrepreneur Justin Floyd and Soumaya Hamzaoui. For more information, please visit www.redcloudtechnology.com and connect on LinkedIn.

Forward-Looking Statements

The information in this press release may include forward-looking statements within the meaning of the federal securities laws. These statements generally relate to future events or our future financial or operating performance. Words such as “expect,” “project,” “estimate,” “believe,” “anticipate,” “intend,” “plan,” “seek,” “forecast,” “target,” “predict,” “may,” “should,” “would,” “could,” and “will,” the negative of these terms and similar expressions are intended to identify forward-looking statements. Forward-looking statements are based on management’s current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict, including, but not limited to, the size and completion of the private placement with the Company’s Chief Executive Officer, the off-setting of financial liabilities owned by the Company to the Company’s Chief Executive Officer, the Company’s ability to build a transformational infrastructure for global trade and whether such infrastructure will successfully provide value to all supply chains. As a result, actual results could differ materially from those indicated in these forward-looking statements. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements described in “Cautionary Note Regarding Forward-Looking Statements,” “Item 3. Key Information – D. Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in RedCloud’s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission, as well as the Company’s periodic reports and other filings with the SEC. RedCloud undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release.

Contacts

Investor Relations
investor.relations@redcloudtechnology.com 

Media Relations
media@redcloudtechnology.com